Compare UBCP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | PLRX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 93.3M |
| IPO Year | N/A | 2020 |
| Metric | UBCP | PLRX |
|---|---|---|
| Price | $13.25 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 3.3K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.24 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $1.10 |
| 52 Week High | $15.64 | $15.27 |
| Indicator | UBCP | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 32.46 |
| Support Level | $13.21 | $1.48 |
| Resistance Level | $13.40 | $1.63 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 100.00 | 25.20 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.